Breast Cancer Research and Treatment

, Volume 26, Issue 3, pp 267–274 | Cite as

Expression of mdr1 gene in human breast primary tumors and metastases

  • Elisabeth Hennequin
  • Chantal Delvincourt
  • Christiane Pourny
  • Jean-Claude Jardillier
Report

Summary

Expression of mdr1 gene has been evaluated in 34 tumor samples obtained from breast cancer patients who were classified according to their treatment, and clinical follow-up. No gene amplification was found. mdr1-RNA was never detected in 29 primary breast tumors including 5 samples from patients previously treated by 6 courses of 5-fluorouracil, epirubicin, cyclophosphamide (FEC). On the other hand, mdr1-RNA expression was detected in 1 local recurrence and 2 out of 3 metastases, all of them being treated and exhibiting a poor evolution. A second, untreated local recurrence remained negative. Clinical follow-up for 7 to 48 months in patients receiving chemotherapy showed that absence of mdr1-RNA could not be an accurate factor of satisfactory response to chemotherapy. But, all the patients with detectable mdr1-RNA exhibited a poor evolution and response to treatment. In conclusion, evaluation of mdr1-RNA seemed to be of little interest in primary breast tumors. However, the concomitant presence of an mdr1-RNA and a metastatic phenotype could give a new insight into the relationship between invasive and resistance properties of cancer cells. Such situations would need to be analyzed very carefully for a better utilization of chemotherapy.

Key words

breast cancer chemotherapy metastasis multidrug resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Scotto KW, Biedler J, Melera PW: Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232: 751–755, 1986Google Scholar
  2. 2.
    Endicott J, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137–171, 1989Google Scholar
  3. 3.
    Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263M: 12163–12166, 1988Google Scholar
  4. 4.
    Veda K, Cardelli C, Gottesman M, Pastan I: Expression of a full-length cDNA for the human MDR1 P-glycoprotein gene confers multidrug-resistance. Proc Natl Acad Sci USA 84: 3004–3008, 1987Google Scholar
  5. 5.
    Georges E, Bradley G, Gariepy J, Ling V: Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152–156, 1990Google Scholar
  6. 6.
    Dufer J, Akeli MG, Jeannesson P, Desplaces A, Jardillier JC: Quantitative morphological analysis of adriamycin-resistant human K 562 leukemic cells. Cytometry 10: 37–43, 1989Google Scholar
  7. 7.
    Warren L, Jardillier JC, Ordentlich P: The secretion of lysosomal enzymes by drug-sensitive and multidrug-resistant cells. Cancer Res 51: 1996–2001, 1991Google Scholar
  8. 8.
    Hindenburg AA, Baker MA, Gleyzer E, Stewart WJ, Case N, Tarib RN: Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res 47: 1421–1425, 1987Google Scholar
  9. 9.
    Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879–2887, 1987Google Scholar
  10. 10.
    Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Priker R, Green A, Crist W, Brodeus GM, Lieber M, Cossman J, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–123, 1989Google Scholar
  11. 11.
    Merkel DE, Fuqua SAW, Hill SM, McGuire WL: P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens. In: Prediction of response to cancer therapy. Alan R Liss, Inc, 1988, pp 61-73Google Scholar
  12. 12.
    Verrelle P, Meissonnier F, Finck Y, Feillet V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111–116, 1991Google Scholar
  13. 13.
    Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Human Pathol 21: 787–791, 1990Google Scholar
  14. 14.
    Giavazzi R, Miller L, Hart IR: Metastatic behavior of an adriamycin-resistant murine tumor. Cancer Res 43: 5081–5086, 1983Google Scholar
  15. 15.
    Hanania N, Boyano MD, Mangin C, Poupon MF: Oncogene and mdr1 gene expression in rat rhabdomyosarcoma sublines of different metastatic potential. Anticancer Res 11: 473–780, 1991Google Scholar
  16. 16.
    Maniatis T, Fritsche EG, Sambrook J: Molecular cloning, a laboratory manual. NY: Cold Spring Harbor Laboratory, 1982Google Scholar
  17. 17.
    Roninson IB, Chin JE, Choi K, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I: Isolation of human MDR DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci 83: 4538–4542, 1986Google Scholar
  18. 18.
    Keith WN, Stallard S, Brown R: Expression of mdr1 gene and gst-π in human breast tumours: comparison toin vitro chemosensitivity. Br J Cancer 61: 712–716, 1990Google Scholar
  19. 19.
    Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, Poplack DG, Cossman J, Myers CE, Cowan KH: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49: 1422–1428, 1989Google Scholar
  20. 20.
    Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R: MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27: 1352–1355, 1991Google Scholar
  21. 21.
    Schneider J, Bak M, Efferth Th, Kaufmann M, Mattern J, Volm M: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815–818, 1989Google Scholar
  22. 22.
    Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS: Prediction of doxorubicin resistancein vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81: 696–701, 1989Google Scholar
  23. 23.
    Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R: Expression of P-glycoprotein in breast cancer tissue andin vitro resistance to doxorubicin and vincristine. Eur J Cancer 27: 155–158, 1991Google Scholar
  24. 24.
    Wishart GC, Plumb JA, Going JJ, Mc Nicol AM, Mc Ardle CS, Tsuruo T, Kaye SB: P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 67: 758–761, 1990Google Scholar
  25. 25.
    Sugawara I, Kataoka I, Morishita Yet al.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48: 1926–1929, 1988Google Scholar
  26. 26.
    Noonan KE, Beck C, Holzmayer TAet al.: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160–7164, 1990Google Scholar
  27. 27.
    Georges E, Bradley G, Gariepy Jet al.: Detection of P-glycoprotein isoforms by gene specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152–156, 1990Google Scholar
  28. 28.
    Finstad CL, Yin BWT, Gordon CM, Fererici MG, Welt S, Lloyd KO: Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis. J Histochem Cytochem 39: 1603–1610, 1991Google Scholar
  29. 29.
    Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE: Enhancement of anthracycline growth inhibition in parent and multidrug-resistant chinese hamster ovary cells by cyclosporin and its analogues. Cancer Res 49: 6275–6279, 1989Google Scholar
  30. 30.
    Hall KS, Endresen L, Huitfeldt HS, Rugstad HE: Induction ofin vitro resistance to 4′-epidoxorubicin and cis-dichloro-diammineplatinum in hepatoma cells. Anticancer Res 11: 817–823, 1991Google Scholar
  31. 31.
    Schott B, Robert J: Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and resistant rat glioblastoma cells. Biochem Pharmacol 38: 167–172, 1989Google Scholar
  32. 32.
    Debal V, Morjani H, Millot JM, Angiboust JF: Determination of vinorelbine (Navelbine) in tumour cells by high-performance liquid chromatography. J Chromatogr 581: 93–99, 1992Google Scholar
  33. 33.
    Beck W: Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerase in drug action and resistance. J Natl Cancer Inst 81: 1683–1685, 1989Google Scholar
  34. 34.
    Ganapathi R, Grabowski D, Schmidt H, Bell D, Melia M: Characterizationin vitro andin vivo of progressively adriamycin-resistant B16-B16 mouse melanoma cells. Cancer Res 47: 3464–3468, 1987Google Scholar
  35. 35.
    Talmadge JE, Benedict K, Madsen J, Fidler IJ: Development of biological diversity and susceptibility to chemotherapy in murine cancer metastasis. Cancer Res 44: 3801–3805, 1984Google Scholar
  36. 36.
    Chin KV, Veda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459–462, 1992Google Scholar
  37. 37.
    Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 53: 747–754, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Elisabeth Hennequin
    • 1
  • Chantal Delvincourt
    • 1
  • Christiane Pourny
    • 2
  • Jean-Claude Jardillier
    • 1
  1. 1.Laboratoire de BiochimieGIBSAReims CédexFrance
  2. 2.Département de CliniqueInstitut Jean GodinotReims CédexFrance

Personalised recommendations